Sign in
4

Changes in Ownership

Fulcrum Therapeutics, Inc. Filed Acc 0000899243-22-024525

Options or other derivatives

  • Director acquired 19,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Haviland Kate Director 2022-06-27 Grant or award · Stock Option (right to buy) +19,000 19,000 D: show line 1 in the form
Loading xslF345X03/doc4.xml…